Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Viral Infections, Non-HIV

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Lancet

Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S

doi: 10.1016/S0140-6736(21)00947-8

Viral Infections, Non-HIV

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

N Engl J Med

Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele MT, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, Lovecchio F, Lee J, Barter D, Brackney M, Fridkin SK, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin MY, Mayer J, Kwon JH, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani JR, Schrag SJ, Vaccine Effectiveness among Healthcare Personnel Study Team.

doi: 10.1056/NEJMoa2106599

Viral Infections, Non-HIV

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

N Engl J Med

Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU, C4591001 Clinical Trial Group.

doi: 10.1056/NEJMoa2110345

Viral Infections, Non-HIV

Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

Rheumatology (Oxford)

Furer V, Zisman D, Kibari A, Rimar D, Paran Y, Elkayam O

doi: 10.1093/rheumatology/keab345

Viral Infections, Non-HIV

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration

Vaccine

Desai AP, Desai AP, Loomis GJ

doi: 10.1016/j.vaccine.2021.06.058

Further Publications Infectiology

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel

Clin Microbiol Infect

Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-Well Y

doi: 10.1016/j.cmi.2021.06.036

Viral Infections, Non-HIV

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

Lancet

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA, ComfluCOV Trial Group.

doi: 10.1016/S0140-6736(21)02329-1

Viral Infections, Non-HIV

The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination

Swiss Med Wkly

Haaf P, Kuster GM, Mueller C, Berger CT, Monney P, Burger P, Stämpfli SF, Attenhofer Jost CH, Zellweger MJ, Osswald S, Donner BC, Koestner SC, Tanner FC

doi: 10.4414/smw.2021.w30087

Viral Infections, Non-HIV

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Vaccine

Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, Leav B, mRNA-1273 Study Group.

doi: 10.1016/j.vaccine.2021.02.007

Related content

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series

Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine